Zealand Pharma A/S 11/7/2024 Earnings Results & Report

Zealand Pharma A/S EPS Results

• Actual EPS: N/A
• Consensus EPS: -$0.62
• Beat/Miss: N/A
• One Year Ago EPS: N/A
• EPS Beat Rate: 5 of last 8 quarters

Zealand Pharma A/S Revenue Results

• Actual Revenue: N/A
• Expected Revenue: $2.68 million
• Beat/Miss: N/A
• YoY Revenue Growth: N/A

Zealand Pharma A/S (OTCMKTS:ZLDPF) is a biotechnology company headquartered in Denmark that discovers, develops and commercializes peptide-based medicines. Its research focuses primarily on metabolic and gastrointestinal diseases, including obesity, diabetes and rare disorders. The company develops therapies designed to address significant unmet medical needs through its expertise in peptide chemistry and drug delivery.

Zealand’s marketed product portfolio includes Zegalogue (dasiglucagon), an emergency treatment for severe hypoglycemia in people with diabetes. The company has also developed several investigational medicines, including petrelintide, an amylin analog being studied for weight management, and other peptide-based candidates for metabolic and gastrointestinal conditions. Zealand previously discovered lixisenatide, which was developed and commercialized through a collaboration with Sanofi under the names Adlyxin and Lyxumia.

Founded in 1998, Zealand Pharma serves international markets through its own activities and collaborations with pharmaceutical partners. Its development programs have included partnerships with companies such as Boehringer Ingelheim, particularly in obesity and related metabolic diseases. Zealand is led by President and Chief Executive Officer Adam Steensberg and is headquartered in Søborg, Denmark.